Skip to main content
Premium Trial:

Request an Annual Quote

Illumina and Genomas to Co-Develop SNP, Haplotype Panels for Metabolic Syndrome

NEW YORK, July 20 (GenomeWeb News) - Illumina and Genomas said today that they will co-develop SNP- and haplotype-based gene marker panels related to metabolic syndrome that Illumina may commercialize upon validation.

 

Genomas said it will use Illumina's BeadStation 500GX benchtop SNP genotyping system to identify diagnostic markers that could be used as PhysioTypes - predictors that Genomas is developing that incorporate haplotypes along with physiological and clinical information and demographic data. Genomas said it will develop PhysioTypes to help predict patient response to exercise, diet, and drug regimens for the treatment of  obesity and the related metabolic syndromes of diabetes and cardiovascular disease.

 

Upon validation, Illumina said that the SNP and haplotype panels that Genomas discovers "may become available to Illumina customers as products under a royalty-bearing license."

 

Additional terms of the agreement were not provided.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.